GLP1R and prostate carcinoma: Both in vitro and in vivo experiments utilizing GLP-1R agonist exendin-4 demonstrated decreased proliferation of prostate cancer cell lines by inhibiting the extracellular signaling-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) pathway, independent of the androgen receptor axis[4].